Eptifibatide (Integrilin)

Benefits

About Eptifibatide (Integrilin)

Eptifibatide is a synthetic cyclic heptapeptide derived from the Lys-Gly-Asp (KGD) recognition sequence of barbourin, a disintegrin protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Marketed under the brand name Integrilin, eptifibatide received FDA approval in 1998 and remains a cornerstone antiplatelet agent used in interventional cardiology. It functions as a reversible, competitive antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, the final common pathway mediating platelet aggregation. The GP IIb/IIIa receptor is the most abundant integrin on the platelet surface, with approximately 80,000 copies per platelet. Upon platelet activation, this receptor undergoes a conformational change that enables high-affinity binding of fibrinogen and von Willebrand factor, effectively cross-linking adjacent platelets and forming a stable thrombus. Eptifibatide blocks this process by occupying the ligand-binding site on activated GP IIb/IIIa, preventing fibrinogen bridging between platelets. Clinically, eptifibatide is indicated for the management of patients with acute coronary syndromes (unstable angina and non-ST-elevation myocardial infarction) who are being managed medically or with percutaneous coronary intervention (PCI). Two landmark trials established its efficacy: the PURSUIT trial demonstrated a significant reduction in the composite endpoint of death or myocardial infarction at 30 days in ACS patients, while the ESPRIT trial showed substantial benefit in patients undergoing elective coronary stenting, with a 37% relative risk reduction in death or MI at six months. Eptifibatide is administered exclusively by the intravenous route in monitored hospital settings. Its pharmacokinetic profile is characterized by linear, dose-proportional kinetics, rapid onset of action, a short elimination half-life of approximately 2.5 hours, and rapid reversibility of platelet inhibition within 4-8 hours of discontinuation. About 50% of the drug is cleared renally, requiring dose adjustment in patients with moderate renal impairment.

Who Should Consider Eptifibatide (Integrilin)

• Patients with non-ST-elevation acute coronary syndromes (unstable angina or NSTEMI)
• Patients undergoing percutaneous coronary intervention or coronary stenting
• High-risk cardiac patients with elevated troponin or ST-segment changes
• Patients with recurrent ischemia despite standard antiplatelet therapy
• Individuals requiring bridging antiplatelet therapy before urgent PCI

How Eptifibatide (Integrilin) Works

Eptifibatide exerts its antiplatelet effect through selective, reversible, competitive inhibition of the glycoprotein (GP) IIb/IIIa receptor on the platelet surface. GP IIb/IIIa (also known as integrin αIIbβ3) is the most abundant receptor on platelets and serves as the final common pathway for platelet aggregation regardless of the initial activation stimulus (thrombin, ADP, collagen, or thromboxane A2). When platelets are activated, GP IIb/IIIa undergoes a conformational change from a low-affinity to a high-affinity state, enabling it to bind soluble fibrinogen and von Willebrand factor, which cross-link adjacent platelets to form a growing thrombus. Eptifibatide is a cyclic heptapeptide containing a Lys-Gly-Asp (KGD) pharmacophore motif modeled after barbourin, a disintegrin from pygmy rattlesnake venom. The KGD sequence mimics the Arg-Gly-Asp (RGD) recognition site that fibrinogen uses to bind GP IIb/IIIa. By competitively occupying this binding site, eptifibatide prevents fibrinogen from bridging activated platelets, thereby blocking aggregation. Unlike abciximab (a monoclonal antibody fragment), eptifibatide binds with lower affinity but higher specificity, resulting in faster dissociation from the receptor and more rapid recovery of platelet function after drug discontinuation. At therapeutic concentrations, eptifibatide achieves greater than 80% inhibition of platelet aggregation, with platelet function returning to near-normal levels within 4-8 hours of cessation of infusion.

What to Expect

Dosing Protocol

Note: Eptifibatide (Integrilin) is an FDA-approved cyclic heptapeptide glycoprotein IIb/IIIa receptor antagonist used exclusively in the acute hospital setting for patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). It is supplied as a ready-to-use sterile solution for intravenous administration and does not require reconstitution with bacteriostatic water. Dosing is weight-based, typically 180 mcg/kg IV bolus followed by a continuous infusion of 2 mcg/kg/min. For PCI, a double-bolus regimen is standard, with a second 180 mcg/kg bolus administered 10 minutes after the first. The infusion may continue for up to 18-24 hours post-PCI or up to 72 hours in medically managed ACS. Eptifibatide must be used under close medical supervision with continuous hemodynamic monitoring and platelet count surveillance.

How to Inject Eptifibatide (Integrilin)

Eptifibatide is administered exclusively via the intravenous route in a hospital or catheterization laboratory under continuous hemodynamic monitoring. For acute coronary syndromes managed medically, the standard regimen is a 180 mcg/kg IV bolus followed immediately by a continuous infusion of 2 mcg/kg/min for up to 72 hours. For PCI, a double-bolus regimen is used: 180 mcg/kg IV bolus immediately before the procedure, followed by a 2 mcg/kg/min continuous infusion plus a second 180 mcg/kg bolus 10 minutes after the first. The infusion continues for 18-24 hours post-PCI (minimum 12 hours). In patients with creatinine clearance below 50 mL/min, the infusion rate is reduced to 1 mcg/kg/min. Eptifibatide should be administered through a dedicated IV line or Y-site compatible with normal saline or D5W. Platelet counts must be monitored within 6 hours of bolus and daily thereafter. Activated clotting time should be maintained at 200-300 seconds when co-administered with heparin.

Cycling Protocol

Pharmacokinetics

Side Effects

Bleeding is the most significant adverse effect of eptifibatide therapy, occurring primarily at vascular access sites (femoral artery puncture) in patients undergoing PCI. Major bleeding events include gastrointestinal hemorrhage, genitourinary bleeding, retroperitoneal hemorrhage, and rarely intracranial hemorrhage. Thrombocytopenia (platelet count below 100,000/mm³) occurs in approximately 1-3% of patients, with acute profound thrombocytopenia (below 20,000/mm³) reported in 0.1-0.2% of cases. Hypotension is a commonly observed hemodynamic effect during infusion. Other reported adverse reactions include nausea, headache, and back pain. Hypersensitivity reactions including anaphylaxis have been reported rarely. The risk of bleeding is substantially increased when eptifibatide is co-administered with heparin, aspirin, or other antiplatelet and anticoagulant agents, which is the standard clinical practice. Platelet counts and hemoglobin levels should be monitored closely during and after administration.

Contraindications

Drug Interactions

Storage & Stability

Molecular Profile

Related Peptides

Bivalirudin (Angiomax)

Immune

Icatibant (Firazyr)

Immune

Ziconotide (Prialt)

Healing & Recovery

References

1. Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes (PURSUIT Trial)PubMed 9705684
2. Platelet Glycoprotein IIb/IIIa Integrin Blockade with Eptifibatide in Coronary Stent Intervention: The ESPRIT TrialPubMed 11368699
3. INTEGRILIN (eptifibatide) Injection — FDA Prescribing InformationFDA Label
4. Clinical Pharmacology of EptifibatidePubMed 9291241